Eli Lilly and Company has emerged as in the manufacturing of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant potential to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepatide involves a series of carefully controlle… Read More